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THE REGULATION OF MITOCHONDRIAL UNCOUPLING PROTEINS IN THE HEART, 
Karl R. Laskowski, Maria Volkova, and Raymond R. Russell. Section of Cardiovascular 
Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, 
CT.  The mitochondrial uncoupling proteins (UCPs) are a recently discovered group of proteins 
that are present in the inner mitochondrial membrane and mediate a variety of important 
functions. Involved in transmembrane proton transport, UCPs regulate cellular metabolism as 
well as prevent reactive oxygen species formation (ROS) and detoxify exogenous ROS. In the 
heart, these proteins may protect tissue during times of ischemic or metabolic stress. Also 
activated during metabolic stress is AMP-activated protein kinase (AMPK), which has been 
shown to provide cardioprotection during ischemia/reperfusion. We hypothesized that AMPK 
activation plays a role in upregulating the expression of uncoupling proteins UCP2 and UCP3 in 
the heart. Using both tissue and cellular models, we demonstrate that pharmacologic activation of 
AMPK with the AMP-analogue, AICAR, leads to increases in UCP2 and UCP3 mRNA and 
protein expression at both one-hour and twenty-four hour incubation time points. Furthermore, 
we identify a segment of the UCP3 promoter that can mediate AMPK-activated transcription. We 
conclude that AMPK activation appears to induce increased UCP expression, and that such an 
effect is mediated through an interaction with a specific portion of the UCP3 promoter. These 
findings support the idea that some degree of the cardioprotective effects observed with AMPK 
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Structure and Function 
The mitochondrial uncoupling proteins, or UCPs, are a group of recently 
discovered proteins found in the inner mitochondrial membrane in various mammalian 
tissues. Uncoupling proteins are members of the superfamily of anion carrier proteins that 
regulate the mitochondrial membrane potential. This membrane potential is created by 
the transfer of protons (generated by citric acid cycle flux) from the mitochondrial matrix 
to the space between the inner and outer mitochondrial membranes via the 
oxidation/reduction reactions of the electron transport chain.  
 
Figure 1. Uncoupling protein function. TCA cycle metabolism of NADH and FADH2 generate a proton 
gradient that is utilized by ATP-synthase to create high-energy phosphates (ATP) or is “wasted” through 
uncoupling proteins that provide an alternate path for protons to cross the inner mitochondrial membrane. 
Adapted from Brownlee, M. Biochemistry and molecular cell biology of diabetic complications, Nature 
2001; 414: 813-820. 
 
The proton gradient drives mitochondrial ATP synthesis by F0F1-ATPase, which, 
in turn, dissipates the mitochondrial membrane potential. Under steady-state conditions, 
this membrane potential is determined by balance between the efflux of protons through 
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the electron transport chain and influx through the F0F1-ATPase. Like F0F1-ATPase, 
UCPs cause dissipation of the mitochondrial membrane potential through transport of 
protons from the space between the inner and outer mitochondrial membranes back into 
the mitochondrial matrix. However, in contrast to F0F1-ATPase, no ATP is synthesized 
by proton conductance through the UCPs and thus, they act as uncouplers of oxidative 
phosphorylation. 
The first described uncoupling protein, UCP1 or thermogenin, was found to 
dissipate the proton gradient in an “energy wasting” manner, creating heat instead of the 
high-energy phosphate, ATP.1 Largely restricted to brown adipose tissue, UCP1 is 
responsible for nonshivering thermogenesis. Subsequently, several proteins similar to 
UCP1 were identified based on sequence homology, establishing a family of UCPs. 
UCP2 was the first structural homolog of UCP1 to be described.2, 3 UCP2 appears to be 
present in a variety of tissues throughout the body, although the presence of UCP2 
protein in heart is the issue of some controversy and may be species-dependent.4, 5  
Like UCP2, uncoupling protein 3 (UCP3) is an inner mitochondrial membrane 
protein with significant structural homology to UCP1. However, UCP3 appears to be 
present in the heart muscle of mice, rats, and humans.  
While the expression of UCP3 in the heart is fairly well established, there remains 
conflicting data regarding the relative expression of UCP2 and UCP3 both between 
tissues and between species. There may also be substantial differences in the proteins’ 
function depending on where they are located.2, 6, 7 This variation has greatly complicated 
the study of the UCPs and much remains to be elucidated concerning the function of the 
UCPs.  For example, while the primary function of UCP1 is widely agreed to be heat 
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generation in brown fat, the physiologic roles of UCPs 2 and 3 are less certain and remain 
the subject of ongoing experimentation and debate.1, 8 Supporting the idea of different 
functions is data demonstrating that UCP1 is upregulated by exposure to cold 
temperatures and is critical for tolerance to cold, while UCP2 and UCP3 expression are 
not effected by cold, but are upregulated in response to fasting.9, 10 
Multiple studies have suggested that these UCP2 and UCP3 may function in 
regulating metabolism: specifically, in the regulation of fatty acid oxidation or ATP 
production.11 Some authors have hypothesized that the UCPs act as pores through which 
fatty acids can enter the mitochondria and undergo oxidation.12, 13 While other previous 
studies have demonstrated that UCP3 knockout mice have lower rates of whole body 
fatty acid oxidation.14 Furthermore, overexpression of UCP2 or UCP3 in cultured muscle 
or insulinoma cells increases the rate of fatty acid oxidation and decreases the rate of 
glucose oxidation when fatty acids are present.15, 16 Yet metabolic effects may not be the 
primary function of the UCPs. 
Given the similar structures of the mitochondrial uncoupling proteins and the 
known function of UCP1, it is not surprising that UCPs 2 and 3 also appear mediate some 
degree of proton leak within the mitochondria.17 However, as mentioned above, UCP2 
and UCP3 do not appear to be involved in significant thermogenesis.  Although UCP2 
and UCP3 are expressed in brown fat, previous research in UCP1-deficient adipocytes 
demonstrated that thermogenesis was almost entirely dependent on the presence of 
functional UCP1 proteins.18 It has been proposed that the major function of UCP2 and 
UCP3 is related to the dissipation of the mitochondrial proton gradient, albeit not to 
produce heat. This function has important implications with respect to cellular protection. 
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Specifically, by reducing the electrical potential across the inner membrane, the UCPs 
reduce production of superoxide radicals at complex I of the mitochondrial respiratory 
chain.19 Supporting this hypothesis are observations from isolated skeletal mitochondria 
harvested from mice: reactive oxygen species production is significantly increased in 
UCP3 null animals compared to wild-type animals.20 In addition to preventing 
“endogenous” reactive oxygen species production by the mitochondria, UCPs may also 
detoxify “exogenous” reactive oxygen species. Specifically, overexpression of UCP1 in 
cultured cardiac myocytes protects against apoptosis induced by the addition of hydrogen 
peroxide.23 
This role in mediating reactive oxygen species production has led to the 
hypothesis that the UCPs protect against oxidative damage. This has been best 
established in the neurologic system.21, 22 However, as discussed below, this effect has 
also been demonstrated in pathologic states in the heart, such as ischemia/reperfusion 
injury, and may be relevant to other clinical scenarios such as heart failure and drug-
induced cardiotoxicity (e.g. doxorubicin).  
UCPs in Reperfusion, Ischemia, and Atherogenesis 
As mentioned above, UCPs may perform essential functions in ischemic heart 
disease. In fact, increasing UCP expression in the heart may be a useful therapeutic 
strategy as multiple studies have demonstrated a significant protective effect of the UCPs 
in cardiac ischemia/reperfusion injury.4 For example, H9c2 cells overexpressing UCP1 
were more likely than their “wild-type” counterparts to survive hypoxia/reoxygenation 
exposure.24 Similarly, overexpression of UCP1 in isolated perfused mouse hearts 
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improved functional recovery (as measured by contractility and oxygen consumption) 
after ischemia and reperfusion.25  
Consistent with their potential role in limiting oxidative damage in “at-risk” 
myocardium, the UCPs have been observed to increase in cardiomyocytes adjacent to 
regions of recent infarction. In a study of post-MI ventricular dilation, myocardial 
infarction was induced in Sprague-Dawley rats resulting in a 60% increase in left 
ventricular end-diastolic dimension. The authors noted an almost two-fold increase in 
UCP2 mRNA expression in the tissue surrounding the infarct zone compared to sham-
operated rats.26 They hypothesized that this increased UCP expression may be 
contributing to the pathologic remodeling process by inducing a low-energy state in the 
surviving myocardium. However, given the cardioprotective data reviewed above, it 
seems more likely that UCP upregulation prevented further myocyte death through 
limiting oxidative damage in the vulnerable peri-infarct region. It is of interest to note 
that another “low-energy state”, fasting, is associated with an increase in UCP2 and 
UCP3 expression, suggesting that the energy wasting effect of these UCPs is negligible.27 
In addition to preventing cell damage and death due to the increased oxidative 
stress of reperfusion, there is evidence supporting the theory that the UCPs protect the 
heart during the preceding periods of ischemia. A recent study has demonstrated a direct 
correlation between the level of UCP2 and UCP3 expression and the degree of ischemic 
preconditioning attained by rat cardiomyocytes.28 The authors further observed that UCP 
mRNA and protein expression were inversely associated with infarct size, and that UCP 
depletion (with RNAi) attenuated or abolished myocyte recovery in vitro after anoxic 
insult.  
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In addition to protecting the heart from both ischemic and reperfusion-induced 
damage, UCPs may prevent ischemia entirely, through limiting atherosclerotic plaque 
formation. Reconstitution of the bone marrow of irradiated LDL-receptor deficient mice 
fed a high-cholesterol, atherogenic diet with UCP2 null bone marrow cells has been 
shown to result in larger atherosclerotic lesions in the aorta.29 It is believed that the UCP2 
null monocytes created by the bone marrow transplantation produce more hydrogen 
peroxide than wild-type monocytes. This increase in hydrogen peroxide production 
results in greater vascular inflammation and endothelial cell activation, important initial 
steps in atherogenesis. Also supporting this theory that UCPs protect against 
atherosclerotic plaque formation, a common single nucleotide polymorphism (-866 
G A) of the human UCP2 gene has been shown to be associated with the presence of 
carotid atherosclerosis.30 Furthermore, individuals homozygous for this allele had double 
the risk for coronary heart disease as compared to people with the alternate allele.31 
Heart Failure and ROS 
The observations discussed above suggest a significant role for UCPs in 
protecting the heart from atherosclerosis, ischemia, and ischemia/reperfusion injury. 
Other research has demonstrated a clear association between ROS and the development 
of heart failure (implying a possible further connection between UCPs and CHF).32, 33 In 
patients with heart failure, markers of increased oxidant stress have been demonstrated in 
both pericardial fluid and blood.34, 35 Furthermore, alterations in the ability to regulate 
oxidant stress are often present. Specifically, in failing hearts, decreases in the expression 
and activity of enzymes involved in the detoxification of reactive oxygen species, 
including catalase and manganese superoxide dismutase, can be observed.36, 37 While 
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these changes may be the result, rather than the cause of heart failure, the observed 
association between genomic changes in the expression of the detoxification enzymes 
and the risk of heart failure suggests a genetic predisposition, and a causal relationship. 
For example, polymorphisms in genes coding for superoxide dismustase are associated 
with an increased risk for the development of idiopathic dilated cardiomyopathy.38-40 
Reactive oxygen species also contribute to the progression of heart failure. In 
addition to the serum markers of oxidant stress, increased levels of reactive oxygen 
species have been reported in heart tissue samples from patients with longstanding 
congestive heart failure.37 In a study of the role of reactive oxygen species in established 
heart failure (in patients with hypertrophic cardiomyopathy), endomyocardial biopsy 
samples demonstrated that lipid peroxidation, a marker of oxidative stress, was 
significantly elevated as compared to individuals without heart failure.41 Furthermore, 
this level of lipid peroxidation was directly correlated with both left ventricular end-
diastolic diameter and end-systolic diameter, and inversely correlated with left ventricular 
ejection fraction. Taken together, these data suggest a possible pathophysiologic role for 
oxidative stress in the development and progression of heart failure. 
With this background, the importance of decreasing oxidant stress in the failing 
heart is easily understood. The efficacy of many proven heart failure therapies involves, 
at least in part, protection of the myocardium from the detrimental effects of ROS. It has 
been suggested that the beneficial effects of angiotensin converting enzyme inhibitors 
(ACEI) in diabetic cardiomyopathy are related to the inhibition of ROS production.42 
This mechanism is supported by the existence of substantial evidence that ROS are 
involved in the development of diabetic heart failure.43, 44  
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Additionally, as a therapy for non-diabetic as well as diabetic heart failure, it 
appears that carvedilol derives some of its effectiveness through its potent antioxidant 
properties.45 In one study utilizing an ischemic rabbit heart model, carvedilol, in 
comparison to bisoprolol (a beta-blocker without antioxidant properties), led to markedly 
decreased cardiac membrane lipid peroxidation.46 In non-ischemic rabbit model of CHF, 
carvedilol treatment decreased measurements of oxidant stress (GSH to GSSG ratio) and 
attenuated ventricular remodeling, cardiac hypertrophy, and myocyte apoptosis whereas 
propranolol and doxazosin (which did not alter oxidative stress) had little effect.45 
Other animal studies have confirmed the role of ROS in the development and 
progression of heart failure. A transgenic mouse model with heart and skeletal muscle-
specific loss of manganese superoxide dismutase develops progressive congestive heart 
failure with specific molecular defects in mitochondrial respiration.38 In this model, 
oxidative stress causes specific morphologic changes in the mitochondria, with excess 
formation of the reactive oxygen species, superoxide radical, reduction of ATP content, 
and transcriptional alterations of genes associated with heart failure. Conversely, 
overexpression of genes involved in the detoxification of reactive oxygen species, such as 
glutathione peroxidase, improved left ventricular function in mice following myocardial 
infarction.47 As discussed below, animal studies of heart failure, including transgenic 
mouse models, have suggested that UCPs may be important in the response of the cardiac 
myocyte to oxidant stress. Given the robust evidence for ROS as a pathophysiologic 
mediator in the development and progression of heart failure,  upregulation of UCPs may 
be a potential target for heart failure therapy. 
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UCPs in Heart Failure 
In developed countries, the most common cause of heart failure is ischemic heart 
disease. Depending on the study population and the method of investigation, the etiology 
of heart failure is attributed to previous myocardial infarction in approximately 50% of 
cases.48 Given the previous discussion of the role of UCPs in the prevention of ischemic 
injury it is easy to see how these proteins might also be relevant to heart failure (by 
preventing ischemic damage to the myocardium through slowing atherosclerosis as well 
as decreasing oxidant stress in ischemic/reperfused cardiomyocytes, UCPs prevent a 
major cause of heart failure). In addition, prior studies have demonstrated that the UCPs 
are downregulated, at least on the mRNA level, in the failing heart, suggesting that their 
downregulation may play a role in the development and/or progression of the disease (a 
hypothesis that would fit nicely with the evidence reviewed above implicating increased 
ROS as a mediator of CHF development and progression—i.e. decreased 
UCP increased ROS  CHF).11, 49, 50  
As discussed above, mice with cardiac deletion of manganese-superoxide 
dismutase develop heart failure from oxidative damage.38 In addition to the findings of 
enhanced oxidant stress, the authors also noted that there was decreased cardiac 
expression of UCP3, perhaps contributing to the pathologic process. 
However, controversy remains as to whether UCPs play a beneficial or 
detrimental role, particularly in the setting of heart failure, because downregulation of 
UCPs in the failing heart could have theoretically opposing effects. A decrease in UCP 
expression would be expected to enhance the coupling between citric acid cycle flux and 
mitochondrial ATP synthesis, enhancing energetic efficiency. This effect would be 
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potentially important in cardiomyocytes that are energetically stressed through the many 
effects of heart failure. However, deceased UCP expression would also have the 
counterbalancing effect of allowing greater production of reactive oxygen species. 
The question then becomes one of whether downregulation of UCP expression in 
the failing heart is beneficial or detrimental and should therapies be developed to increase 
or decrease UCP expression. Would the shunting of protons away from ATP production 
by increasing UCP expression contribute to a low-energy state?51, 52 Given the 
preponderance of evidence implicating increased ROS in the pathogenesis of heart 
failure, it would seem that limiting oxidative stress would be the more pressing goal. 
Addtionally, it has been argued that, in addition to preventing oxidant stress and 
cardiomyocyte damage, the metabolic effects of the UCPs are actually beneficial to the 
failing heart, and represent an adaptive response to lipid accumulation within the 
mitochondria and subsequent toxicity, and not a maladaptive response.53 Finally, one 
cannot ignore the evidence suggesting that UCP upregulation would prevent heart failure 
development through limiting ischemic damage.  
Whether the decreased UCP expression in CHF is a protective response or a 
pathophysiologic one, it seems clear that the UCPs are intimately involved in the 
development and pathogenesis of heart failure. 
Clinical Relevance 
From a review of the literature, it seems clear that UCPs play an important role in 
two exceptionally important cardiovascular conditions: ischemic heart disease and heart 
failure. Ischemic heart disease causes more deaths and disability and incurs greater 
economic costs than any other illness in the developed world. In the United States, it is 
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estimated that more than 12 million people are afflicted with this disease. With the 
increasing rates of obesity, insulin resistance, and type 2 diabetes mellitus—all clearly 
linked to the development of heart disease—it is projected that the rates of ischemic heart 
disease will only continue to increase, likely becoming the most common cause of death 
worldwide by 2020.54 
Like ischemic heart disease, congestive heart failure is a common and often 
devastating disease of great importance to the world health community. Heart failure is a 
common disease with a prevalence estimated at 1-2% in the general population.55  
Increasingly important as our population ages, this condition can afflict upwards of 7-
10% of the elderly and is often underdiagnosed.56 A diagnosis of heart failure is not a 
trivial matter with one year mortality rates estimated to be between 12 and 45% and 
worse long-term survival than most common cancers.57, 58, 59 The substantial prevalence 
and significant complications of heart failure make it a source of major healthcare 
expenditure to the population at large.  In the United States, more than 900,000 people 
are hospitalized each year for heart failure, creating annual expenses in excess of 6 billion 
dollars.60 Given the important roles of the UCPs in common and devastating clinical 
diseases, a clear understanding of the regulation of these proteins would be extremely 
valuable in developing new potential therapies. 
Regulation of UCPs 
While the mechanisms responsible for regulating UCP expression in various 
tissues (including skeletal muscle, hepatocytes, pancreatic β-cells, and adipocytes) have 
been well studied, the regulation of UCP in the heart is not yet as well characterized. Data 
suggests that UCP expression in the heart is regulated, in part, through peroxisome 
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proliferator-activated receptor (PPAR) α-mediated mechanisms.61 In a mouse heart 
model, PPAR α agonist WY-14,643 increased cardiac UCP2 and UCP3 protein in wild 
type mice but not in PPAR α -/- mice.62  
In addition to the PPAR pathway, there is evidence that UCP expression can be 
increased in skeletal muscle through activation of AMP-activated protein kinase 
(AMPK), a signaling protein kinase that responds to metabolic stress. 63, 64 In one study, 
rats were injected with an AMPK activator (AICAR, described in detail below) for 28 
days after which analysis of skeletal muscle revealed increased levels of UCP3 mRNA 
and protein. Another study utilizing an AMPKα2 knock out model demonstrated 
decreased levels of UCP3 mRNA content.65 Prior to our experiments, it remained unclear 
whether these observations in skeletal muscle were applicable to the heart as well. 
Because of this uncertainty, and the potentially important clinical implications, it is the 




Structure and Function 
AMP-activated kinase (AMPK) is a heterotrimeric protein kinase that serves as a 
key energy regulator in the eukaryotic cell.  First described in the late 1980s, AMPK has 
been implicated in a vast number of metabolic functions.66 Chiefly, AMPK responds to 
changes in the energy stores of the cell by enhancing nutrient uptake, increasing the 
provision of energy, as well as decreasing energy-depleting cell activities with the 
combined result of restoring cellular energy balance.67 This function has led some to 
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describe AMPK as the “fuel gauge” of the mammalian cell and the “guardian of energy 
status” in the heart.68, 69 
The AMPK protein is a complex of three subunits: the catalytic α subunit, and the 
regulatory β and γ subunits. Each of these subunits has two or three isoforms, and twelve 
different isoform combinations appear to be stable as the functional heterotrimeric 
complex.70, 71 However, the majority of cardiac myocyte AMPK appears as an α2β1γ1 
combination, with lesser contributions from α1, β2, γ2, and γ3.72, 73 The expression of 
different isoforms is tissue dependent, with γ3, for example, predominating in skeletal 
muscle but being absent in the heart.68 Apart from the relative prevalence within specific 
tissues, some differences between the various isoforms have been described; specifically, 
variations in cellular localization and in response to cellular AMP levels.70 For example, 
AMPK complexes containing the α2 isoform are preferentially localized within the cell 
nucleus whereas the α1-containing complexes are absent from this compartment.74 
As briefly mentioned above, AMPK functions chiefly as an energy sensor and 
metabolic regulator. AMPK is activated when there is an increased AMP:ATP ratio—that 
is, when energy stores are low.  AMP allosterically activates AMPK while also inducing 
phosphorylation of a threonine residue in the α subunit (Thr 172) by upstream kinases.67 
The AMPK kinases (AMPKK) include the tumor suppressor LKB1 as well as calcium 
calmodulin dependent kinase (CaMKK).75, 76 (Interestingly, the CaMKK pathway appears 
to respond to increased intracellular calcium concentrations rather than AMP:ATP ratio 
and may be an alternative mechanism by which tissue specific regulation is achieved.)  
In addition to inducing phosphorylation (and thus activation) of the α subunit, 
high levels of AMP prevent dephosphosphorylation and subsequent deactivation of the 
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AMPK complex.77 Both the phosphorylation of AMPK by the upstream AMPKK and the 
inhibition of the AMPK phosphatases are prevented by increased concentrations of ATP. 
Thus it is the AMP:ATP ratio that ultimately controls the regulation of AMPK (as an 
aside: it has been shown that AMPK also responds to indirect signals of energy status, 
including glycogen levels—the β subunit of the AMPK protein has a glycogen binding 
domain that responds to high cellular glycogen levels [indicative of adequate energy 
stores] by inhibiting AMPK activation.68, 78). Perturbations in the AMP:ATP balance can 
be caused by physiologic mechanisms (such as exercise) or pathologic stimuli (e.g. heat 
shock and metabolic poisoning which limit ATP production, or ischemia and hypoxia 
which increase ATP consumption).70 Previous research has clearly demonstrated that 
AMPK responds to a variety of these metabolic stressors, including hypoxia, ischemia, 
and oxidative stress.67 
These physiologic stimuli perturb the “resting” balance of AMP relative to ATP.  
AMP is present in the heart in very low concentrations under normal physiologic 
conditions. During periods of ischemia or other types of metabolic stress, the amount of 
ADP rapidly increases.68 In eukaryotic cells, a very active adenylate kinase enzyme 
maintains an equilibrium between ADP and AMP by catalysis of the reaction 
2ADP ATP+AMP. Thus an increase in ADP leads to a quick corresponding increase in 
AMP, and the AMP:ATP ratio varies as approximately the square of the ADP:ATP 




Figure 2. AMP-activated Kinase (AMPK) regulation and function. An increased AMP:ATP ratio indicates 
a negative energy balance in the cell and induces phosphorylation of a threonine residue on the catalytic α 
unit of AMPK by upstream AMPK kinases (e.g. LKB1).  The activated AMPK phosphorylates various 
downstream targets with the net result of increasing cellular energy production while limiting cellular 
energy-expenditure 
 
In response to depleted energy stores, AMPK has a range of effects on tissues 
throughout the body with the goal of limiting ATP consumption while increasing its 
production to restore cellular energy balance.  While many of the molecular pathways 
remain to be elucidated, it is clear that AMPK phosphorylates a range of target proteins, 
“switching on catabolic pathways that generate ATP, while switching off anabolic 
pathways and other nonessential ATP-consuming processes.”70 The energy-expending 
processes that AMPK activation limits include fatty acid, cholesterol and protein 
synthesis. This occurs through a combination of direct protein modification as well as 
modulation of cellular genetic expression.70 In the heart, AMPK activation increases fatty 
acid oxidation and glycolysis as well as glucose uptake by cardiomyocytes.79 Similar 
effects are observed in skeletal muscle. In the liver, fatty acid synthesis, cholesterol 
synthesis and gluconeogenesis are inhibited by AMPK activation. Fatty acid synthesis 
and lipolysis are also decreased in adipocytes. And in the hypothalamus, appetite is 
stimulated.69 The end result of this regulation is to conserve energy within the cell during 
times when stores are low. 
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As stated previously, the exact mechanism of action of many of these pathways 
has yet to be fully defined. It seems likely that many of these effects are mediated 
through signaling cascades involving protein phosphorylation by the AMPK enzyme, but 
some degree of transcription factor modification and differential gene expression is likely 
as well. The uncertainty surrounding the downstream effectors of the AMPK pathways 
make this research project an important endeavor, particularly because AMPK has 
already been proven to exert important protective effects in the heart, and a more clear 
understanding of signaling pathways would allow for potential pharmacologic 
manipulation. 
AMPK and the Heart 
Previous research has demonstrated that AMPK is important in maintaining 
cardiovascular energy balance. Under normal physiologic conditions, AMPK plays a role 
in controlling both skeletal and heart muscle metabolism during exercise.68, 80 Under 
pathologic conditions, AMPK activation leads to translocation of cardiac GLUT4 glucose 
transporters to the sarcolemma and a subsequent increase in cellular glucose uptake.68, 81 
In the ischemic heart, this transition from fatty-acid based metabolism to a greater 
reliance on glucose as an energy source is key to cell survival as nutrients become more 
scarce. 81 In addition, AMPK has been shown to be critical to maintaining myocardial 
energy homeostasis during ischemia by stimulating glycolysis.82, 83 
Past research in our lab has indicated an important role for AMPK in the 
myocardial response to ischemia.  To better characterize the function of AMPK during 
ischemic and post-ischemic reperfusion conditions, transgenic mice with a kinase dead 
(KD) form of the AMPK protein were utilized in a series of experiments. During low-
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flow ischemia and post-ischemic reperfusion in vitro, KD hearts failed to augment 
glucose uptake and glycolysis, although glucose transporter content and insulin-
stimulated glucose uptake were normal. KD hearts also failed to increase fatty acid 
oxidation during reperfusion. Furthermore, KD hearts demonstrated impaired recovery of 
LV contractile function during postischemic reperfusion that was associated with a lower 
ATP content and increased injury compared with wild type hearts. These data suggest 
that AMPK is responsible for activation of glucose uptake and glycolysis during low-
flow ischemia and that it plays an important protective role in limiting damage and 
apoptotic activity associated with ischemia and reperfusion in the heart.79 
AMPK and the UCPs 
AMPK activation has additional effects that are related to regulation of key 
proteins on a transcriptional level. One important effect of AMPK activation in skeletal 
muscle is an increased expression of the UCPs as well as other key metabolic proteins, 
including hexokinase II and GLUT4.81, 84-86 In addition, AMPK activation has been 
shown to be a critical step in the regulation of several nuclear transcription factors, 
including NRF-1, HIF-1α and p300.84, 87, 88 These observations suggest that AMPK may 
exert some of its metabolic effects through direct modification of genetic expression in 
the nucleus.86  
While AMPK activation has been shown to upregulate both UCP3 mRNA and 
protein expression in rat skeletal muscle, a similar association has not been demonstrated 
in the heart. There is some circumstantial evidence that implies such a role. For example, 
PPARγ agonists have been shown to activate AMPK, probably through a mechanism that 
involves increasing the cellular AMP:ATP ratio.89  PPAR pathways are also involved in 
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the upregulation of UCPs, though most evidence for the cardiac UCPs supports a role for 
PPARα rather than PPARγ (which has been shown to activate UCPs in tissues outside the 
heart).90-92 
Given the potential role for UCPs in protecting the cell from oxidative stress, an 
association between increased ROS load and AMPK activation would seem to suggest a 
possible regulatory link. In a series of experiments with NIH-3T3 cells, H2O2 induced 
phosphorylation at the Thr172 activation site of AMPK.  This activation was blocked by 
pretreatment with 0.5% dimethyl sulfoxide, a potent free-radical scavenger.93 Others have 
suggested that AMPK may have an as yet unidentified role in the prevention of reactive 
oxygen species generation.68 These observations favor a potential role for AMPK in the 
regulation of UCPs: decreased energy or increased reactive oxygen species leading to 
AMPK activation would increase expression of the UCPs and prevent excess ROS 
production as well as detoxify existing ROS. We set out to experimentally examine the 
hypothesis that AMPK activation upregulates UCP transcription and translation, and to 
more clearly define the mechanism by which this occurs.  
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STATEMENT OF PURPOSE AND SPECIFIC AIMS 
  
Mitochondrial uncoupling proteins appear to play critical roles in cardiovascular 
metabolism, in protection of the heart during periods of ischemia and post-ischemic 
reperfusion, and in the pathogenesis and potential prevention of heart failure. A more 
complete description of their regulation may lead to important advances in understanding 
the pathophysiology of various heart diseases, and may contribute to the development of 
promising, novel therapies. AMPK controls the metabolic state of virtually all 
mammalian cells, including cardiomyocytes, and is activated under clinically relevant 
stimuli that appear to also induce the upregulation of the UCPs in the heart (ischemia, for 
example). Given these observations, it has been suggested that AMPK controls the 
cardiac expression of UCPs. The set of experiments described in this thesis examined the 
following hypothesis: 
 
      Activation of AMPK leads to an increased expression of the mitochondrial 
uncoupling proteins, UCP2 and UCP3, in the cardiomyocyte. 
 
Specific Aims: 
1. To determine whether pharmacologic activation of AMPK induces an increase in 
UCP2 and UCP3 mRNA utilizing both isolated tissue and cellular cardiomyocyte 
models. 
2. To determine whether pharmacologic activation of AMPK induces an increase in 
UCP2 and UCP3 protein in a cellular cardiomyocyte model. 
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3. To identify any sites of interest in the UCP3 promoter where AMPK, or its 
downstream mediators, may interact to affect an upregulation of UPC3 




Pharmacologic AMPK activation 
To determine whether mitochondrial uncoupling proteins in the heart are 
upregulated via a mechanism involving the activation of AMPK, a series of experiments 
were planned utilizing a pharmacologic activator of AMPK. While AMPK is usually 
activated by an increased AMP:ATP ratio as described above, alterations in this ratio are 
often impractical for experimental investigations. AMPK can be pharmacologically 
activated through the addition of 5-aminoimidazole-4-carboxamide riboside (AICAR).  
AICAR is a cell-permeable adenosine analog that is taken up by the cells and 
phosphorylated to form 5-aminoimidazole-4-carboxamide-1-d-ribofuranosyl-5′-
monophosphate (ZMP), an AMP mimetic.67 ZMP mimics all of the activating effects of 
AMP, although it is much less potent on a mol:mol basis.70, 94 AICAR also blocks 
adenosine re-uptake (as described in more detail below) and this was the motivation 
behind its previous use in clinical trials. 
Throughout all of the experiments described below, AMPK activation was 
achieved using AICAR. In all cases, the activation of AMPK was confirmed by 
evaluation of Thr172 phosphorylation by immunoblot analysis. As described above, 
phosphorylation of the threonine-172 residue on the α-subunit by upstream AMPKK is a 
critical step in the activation of the AMPK complex, and phosphorylation is an accepted 




To examine the role of AMPK in the regulation of cardiac UCP expression, a 
mouse tissue model was used first. C57/BL6 wild-type mice were sacrificed using 
pentobarbital (150 mg/kg, i.p.) and the hearts were harvested and immediately placed in 
ice-cold 0.9% saline. The ventricles were isolated by trimming away any remnants of the 
great vessels as well as the atria. The remaining tissue was placed in an acrylic mouse 
brain slicer with 1.0-mm coronal slicing intervals. The heart was then cut into 1-mm thick 
rings that were then placed in 100-mL Erlenmeyer flasks with either a control buffer 
solution or an “experimental” AICAR solution as described below.  
 
Figure 3. Schematic Representation of Tissue Model Experiments. C57/BL6 wild type mouse ventricles 
were harvested, sectioned, and incubated with or without AICAR. After homogenization, RNA was 
isolated, and quantitative real time PCR performed to determine relative expression of UCPs. 
 
The basic incubation solution consisted of 1x Dulbecco’s phosphate buffered 
saline (DPBS) with 1 mM calcium chloride, 1 mM magnesium chloride, 1% bovine 
serum albumin (BSA), 5 mM glucose and 0.4 mM oleate. To make the control solution, 5 
μl of DMSO was added (as a vehicle control) to 5 ml of the incubation solution described 
above. The “experimental” solution was identical except that 25 μl of 200 mM AICAR 
was added to the 5-mL of incubation solution to yield a 1 mM concentration of AICAR.  
The heart slices were incubated in either control solution or AICAR solution on a 
shaking water bath at 37°C with 100% oxygen for 1 hour or 24 hours. At the end of the 
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incubation, the ventricular slices were snap frozen in liquid nitrogen and stored at -80°C 
until analysis.  
Frozen sections were homogenized using a rotor-stator homogenizer followed by 
5 passes through a 20-gauge needle. RNA was then isolated using the RNeasy mini kit 
(Qiagen) using the protocol suggested by the manufacturer.  RNA concentration was 
determined spectrophotometrically as A 260/280. 
Using the RNA samples, reverse transcription PCR was performed to determine 
the relative expression of UCP2 and UCP3 mRNA. RNA was diluted to 1 µg/11 μl 
concentration. For each reaction, 11 μl of the RNA mixture was added to 1 μl of 
oligo(dT)15 primer (Promega) and mixed. Reverse transcription mastermix was prepared 
(per reaction: 4 μl of 5x first strand synthesis buffer [Roche] + 2 μl of 0.1 M DTT 
[Roche] +1 μl of 10mM dNTPs per reaction [Roche]). Seven microliters of this reverse 
transcription mastermix was added to each reaction and incubated at 42°C for 2 minutes. 
One microliter of Superscript II (Roche) was added to each reaction and the mixture 
returned to 42°C incubation for another 50 minutes. The mixture was then incubated at 
70°C for 15 minutes. RNase H (0.6 μl, Roche) was added to each sample and then 
incubated for 20 minutes at 37°C. The total volume was adjusted to 100 μl by adding 79 
μl of sterile water, and the sample was boiled for 10 minutes. The sample was 
immediately placed on ice and used immediately in PCR reactions, or stored at -80°C. 
The cDNA from the RT-PCR described above was used for qualitative real time 
PCR (qRTPCR) reactions as follows: primers and Taqman probes using a “fam” dye 
were created (Biosearch Technologies) using sequences previously published in the 

























Table 1. Taqman Primers and Probes for quantitative Real Time PCR. Mouse primers and probes were 
used for tissue model experiments (mouse ventricle) while rat primers and probes were used for cellular 
model experiments (H9c2 cells). Table adapted from Young, ME, et. al.61 
 
For the qRTPCR experiments, cyclophilin was selected as a reference 
“housekeeping” gene on the basis that it is present in the cells of interest and thought to 
be unaffected by treatment with AICAR.  In addition, previous work by others in the lab 
had demonstrated that the amplification efficiencies of the cyclophilin reference gene and 
the target UCP2 and UCP3 genes are similar. This observation is critical for meaningful 
analysis with the delta-delta method (described in detail below). 
 A “primer-probe” mix was prepared for each gene of interest (for example, 
UCP2, UCP3 and cyclophilin) with 5 μl of 100 µM probe, 10 μl of 100 µM forward 
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primer, 10 µl of 100 µM reverse primer, and 375 µl of DNAse/RNAse free water. Eight 
μl of cDNA was mixed with this primer-probe mix and 12.5 µl of taqman mastermix 
(Applied Biosystems). 
The qRTPCR was conducted with a DNA Engine Opticon 2 two-color PCR 
Detection System (Bio-Rad) connected to a standard IBM desktop computer.  A typical 
qRTPCR protocol was employed (e.g. incubation at 95°C for 5 minutes followed by 50 
cycles of 95°C for 30 seconds, 60°C for 1 minute, and a plate reading). Quality control 
for the specificity of the amplification product was achieved through gel analysis 
revealing a single band of appropriate size. 
Results were analyzed using the “delta-delta” or “comparative Ct” method. A 
“threshold value” is arbitrarily set along the logarithmic portion of the amplification 
curve. The cycle at which the sample crosses the threshold (or Ct value) is recorded for 
each sample, including the reference gene samples. The target samples, both 
experimental and control (in this case AICAR treated and control incubation buffer 
treated, respectively) are each normalized to the reference gene by subtracting the Ct of 
the reference sample from the Ct values of the experimental samples yielding ΔCt’s for 
each of the target samples. As mentioned above, it is critical that the sample gene has an 
amplification frequency similar to the chosen reference gene—that is, that the slope of 
the logarithmic portion of the curve is similar. If this is not the case, than normalization to 
the reference gene will introduce error into the analysis and make meaningful comparison 
impossible.  
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After normalizing to the reference gene, the “delta delta” value is then calculated 
by subtracting the ΔCt of the mean value for the control sample from the ΔCt of each 
experimentally treated sample. Expressed mathematically, the calculation is as follows: 
delta delta Ct=  ( Ctexperimental - Ctreference ) - ( Ctcontrol - Ctreference ) 
If the amplification efficiencies are similar, this value is an expression of the quantitative 
amount of cDNA that was present at the start of the qRTPCR procedure—that is, the 
relative expression of the gene of interest. To complete the determination of relative gene 
expression, the following calculation is performed:  
relative mRNA = 2-delta delta Ct 
 In this set of experiments, cDNA from the AICAR treated and “control” (or non-
AICAR treated) ventricular samples was analyzed as above. Mean expression values 
were calculated for both experimental and control samples and paired student t-tests were 
used to determine statistical significance (GB-Stat PPC SchoolPak). 
 
Cellular Model 
 Next, experiments were performed utilizing a cellular model. The cellular model 
was used to further support a role for AMPK in the regulation of UCP expression 
(including important quantification of UCP protein levels as well as mRNA) and to 
perform the genetic studies outlined below.  
H9C2 cells were selected because of their rapid doubling time, ease of use, and 
similarity to adult cardiomyocytes. The cells are derived from a neonatal rat myoblastic 
line and retain some of the characteristics of true cardiomyocytes. Unlike 
cardiomyocytes, however, H9C2 cells need not be isolated from harvested tissue, are far 
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easier to maintain, and replicate indefinitely.95 For these experiments, the cells were used 
from passage 1 through passage 15 and then discarded because later generations can 
develop morphology significantly different from typical cardiomyocytes.  
 
Figure 4. Schematic Representation of Cellular Model Experiments. H9C2 Cells were incubated with or 
without AICAR. In one set of experiments mRNA was isolated and then used for quantitative real time 
PCR to determine UCP expression in AICAR treated vs. control cells. In a second set of experiments, cells 
were harvested and protein isolated to determine phospho-AMPK and UCP expression in AICAR treated 
vs. control populations. 
 
Cells were plated under sterile conditions onto 100-mm tissue culture plates with 
high glucose, L-glutamate containing Dulbecco’s Modified Eagle Medium (Gibco) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) and a 1%  penicillin-
streptomycin antibiotic mixture. Subconfluent (70-80%) plates were passaged in a typical 
manner (cells were detached from plates by addition of trypsin, which was subsequently 
inactivated by addition of 5 ml of DMEM/10% FBS media; the cells were then collected 
and sedimented by centrifugation, resuspended in fresh media, and aliquoted onto new 
plates). All cells were stored in a sterile incubator at 37°C and 5% CO2. 
Originally, there was some concern that the 10% FBS media might contain 
growth factors or other substances that would affect AMPK activation and introduce error 
to the planned experiments. Therefore, H9C2 cells were incubated with either high 
glucose (4.5 g/l) or low glucose (1 g/l) DMEM with 0.1% or 1% FBS for 24 hours prior 
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to harvest and immunoblots for phospho-AMPK were performed to determine if these 
culture conditions activated AMPK (described below).  However, all combinations of 
low-FBS media led to super-activation of AMPK such that no difference between 
AICAR treated and control samples could be determined (all samples were maximally 
phosphorylated). A decision was therefore made to incubate all cells with 10% FBS for 
the entirety of the experiments. 
The H9C2 model was used to examine the effect of AMPK activation on UCP2 
and UCP3 mRNA levels in a manner similar to the tissue model experiments described 
above. When 70-80% confluent, H9C2 cells were washed with DPBS, then treated with 1 
mM AICAR in 5-ml of 10% H9C2 media (as described above) or with 5-ml of media 
alone for 1 hour or 24 hours. The cells were again washed with DPBS and harvested as 
per the “cells” protocol in the RNeasy minikit (Qiagen). RNA concentration was again 
determined spectrophotometrically, and reverse transcription PCR was performed in the 
same manner as described above. Using this cDNA,  qRTPCR was then performed as 
previously described. Analysis was again performed using the Opticon 2 (Bio-Rad) 
system and the “delta delta” method.  
To verify that AICAR was in fact activating AMPK, immunoblotting for 
phospho-AMPK was performed. H9C2 cells that were 70-80% confluent were washed 
with cold DPBS. Vacuum suction was then employed to remove all DPBS. Lysis buffer 
mix was prepared by combining 10-ml of CellLytic M Cell Lysis reagent (Sigma), 1 
Complete Proteinase Inhibitor complex tablet (Roche), 100 µl of 1 M sodium fluoride, 
and 10 µl of 1M sodium orthovanadate (Na3VO4). Two hundred microliters of this mix 
was added to each plate. The plates were scraped and the cell lysate was transferred to a 
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microcentrifuge tube. The mixture was centrifuged at 10,000g for 10 minutes. The 
supernatant was removed and stored (precipitate was discarded) and the protein 
concentration subsequently measured spectrophotometrically using the Bradford-
Standard method with a BSA standard. 
Twenty micrograms of protein was combined with 5 µl of 6x protein loading 
buffer and water (if necessary) to a total volume of 25 μl. This mixture was heated to 
100°C for 10 minutes. The protein was then loaded into a 10% NuPage gel (Invitrogen) 
with a kaleidoscope marker (Biorad) and electrophoresis carried out in MES containing 
buffer for 35 minutes at 200V. The separated proteins were then transferred to a 
nitrocellulose membrane (Millipore) by electroblotting at 250 mA for 1.25 hours. The 
membrane was blocked in 5% BSA solution for 1 hour and then incubated overnight at 
2°C with 10 µl of rabbit anti-phosphoAMPK antibody (Cell Signaling) in 10-ml of 5% 
BSA. The next morning, the membrane was washed with tris-buffered saline with tween 
(TBST) buffer three times for 15 minutes each. Secondary antibody (4-µl of donkey anti-
rabbit IgG-HRP [Santa Cruz] in 5 ml of 2.5% BSA solution) was then added for 1 hour at 
room temperature. The membrane was washed again 3 times for 15 minutes each. After 
washing was complete, the membrane was incubated with Chemiluminescent Developer 
Solution (Pierce) for 1 minute, and x-ray film (Kodak) placed in the developer cassette 
with the membrane for approximately 15 minutes. The blot was then stripped to remove 
the antibodies, washed two more times with TBST buffer and blocked in 5% milk for 1 
hour. Then the membrane was incubated overnight at 2°C with 25 μl of goat anti-AMPK 
α2 (R&D Systems) in 10 ml of 5% milk to confirm equal loading of samples. The next 
morning the membrane was washed three times and then incubated with 4 µl of donkey 
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anti-goat IgG-HRP (Santa Cruz). The membrane was again developed with detection 
buffer and an x-ray film record obtained after approximately 10 minutes of exposure. 
Immunoblots were later scanned into a computer. Band intensities from the images were 
quantified using Image J (National Institutes of Health). 
 
Expression of UCP mRNA and protein 
There is some controversy in the literature as to whether UCP mRNA levels truly 
correlate with protein expression.96, 97 For example, while UCP2 mRNA is found in adult 
myocardium, skeletal muscle, and brown adipose tissue, UCP2 protein is generally not 
detected in these tissues.97, 98 In recognition of this potential discrepancy, H9C2 cells 
were treated with AICAR or control solution and then harvested for immunoblot analysis 
of protein expression. Because the uncoupling proteins are found in the mitochondria, a 
mitochondrial isolation protocol was employed to improve the detection of UCP2 and 
UCP3 protein. Plates containing H9C2 cells that were 90-100% confluent were 
trypsinized and the cells collected into centrifuge tubes (4 plates per tube) and spun at 
600g for 5 minutes. The cells were washed with ice cold DPBS and then spun down 
again after which the supernatant was discarded. This step was repeated a second time. 
Approximately 1.5 ml of lysis buffer (5 ml of lysis reagent [Sigma], 1/2 of a Complete 
Protease Inhibitor mini tablet [Roche], 500 µl of 1 M sodium fluoride, and 50 µl of 1M 
sodium orthovanadate) was added to each tube. The samples were then incubated on ice 
for five to ten minutes. At 1-minute intervals, the samples were mixed by drawing them 
up and down 3 times through a 25-gauge needle into a 3 ml syringe. Three milliliters of 
mannitol mitochondrial extraction buffer were added to each sample (extraction buffer 
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contained 5 mM HEPES, 210 mM mannitol, 70 mM sucrose and 1mM EGTA). The 
homogenate was centrifuged at 600g and 4°C for 10 min. The pellet was set aside for 
nuclear protein isolation and subsequently stored for later analysis.  The supernatant was 
transferred to a fresh tube and centrifuged at 11,000g and 4°C for 10 min. The resulting 
supernatant was then discarded and the pellet resuspended in a storage buffer and stored 
at -80°C until analysis. 
Immunoblot analysis was performed in a manner similar to that described above. 
Electrophoresis was performed using 12% NuPage gels (Invitrogen) in MES buffer for 35 
minutes at 200V. Transfer to the nitrocellulose membrane was carried out via the same 
procedure as above. Blocking was achieved with 5% milk solution and the membranes 
were incubated overnight in primary antibody solution (25 µl of rabbit anti-UCP2 
[BioLegend] or 25 µl of anti-UCP3 [Affinity Bioreagents] in 5 ml of 5% milk). 
Secondary antibody (4 µl of donkey anti-rabbit IgG-HRP [Santa Cruz]) was applied the 
next day after washing, and development achieved as above with 20-30 minute 
exposures. After stripping, washing and blocking in 5% milk for one hour, 10 µl of goat 
anti-cytochrome C antibody in 10 ml of 5% milk was applied to the membrane (as a 
loading control) and incubated overnight at 2°C. Secondary antibody (2 µl of anti-goat 
IgG-HRP [Santa Cruz] in 10 ml of 2.5% milk) was then applied and the membrane 
incubated at room temperature for one hour. Development (with approximately 2 minute 
exposure) and analysis were carried out as above.  
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Analysis of the Promoter Region of UCP3 
In order to identify the promoter region of the UCP3 gene that interacts with 
activated AMPK or one of its downstream messengers, luciferase reporter vectors were 
created incorporating different portions of the UCP3 promoter.  
The sequence of the 2100 bp segment preceding the start of transcription was 
downloaded from GeneBank (NIH). Using computer software (Vector NTI [Invitrogen]) 
this promoter was analyzed and divided into three overlapping segments. The full 2000 
bp sequence was termed “long,” the segment from -1977 to -1077 “left,” from -1600 to -
697 “middle,” and -1000 to +20 “right.”  
 
Figure 5. UCP3 Promoter Constructs. In order to better characterize the site of interaction between 
activated AMPK and the promoter segment of the UCP3 gene, the 2000 bp segment preceding the start of 
transcription was cloned, as were three “fragments” named “Left,” “Middle,” and “Right.” 
 
 Heart tissue from a Sprague-Dawley rat was used to extract DNA using a DNeasy 
tissue kit (Qiagen). After obtaining all appropriate primers from the W. M. Keck 
Foundation Biotechnology Resource Laboratory (Yale University), PCR of the 
aforementioned DNA was employed to create the promoter constructs. The primers used 





Name Sequence Tm Length 
Full 
Promoter PRU3F1 ACCCTCAGCCCTACCTGTCCCACAT 63 25 
 PRU3R1 CCGGAGATCTTACCTGTGAGTCTAGCCAAGGT 66 32 
Left PRU3F2 GCTTGAGAAATGTCAGCCCACACTT 60 25 
 PRU3R2 CCGGAGATCTTGACATAGAAGGGAGACTAAAA 63 32 
Middle PRU3F4 GCTGCAGGCAAAGTGGAGGTCTGAA 64 25 
 PRU3R4 CCGGAGATCTAGCAGGATCGTACAGAATGTAT 64 32 
Right PRU3F3 AAGGAATTCTGCTCACCTGCCCCTT 63 25 
 PRU3R3 CCGGAGATCTCCCCTCCTCACCATTCACTGTT 71 32 
Table 2. UCP3 Promoter Primers for Fragment Construction. In order to create UCP3 promoter 
“fragments,” the above PCR primers were designed using Vector NTI software (Invitrogen). All primers 
also included a BglII restriction enzyme site to allow for easy transfer from the T-easy vector to the 
pGL4.18 vector. 
 
After PCR, all of the fragments were subsequently cloned into the pGEM T-easy 
vector (Promega) and subcloned into the luciferase reporter vector pGL 4.18 (Promega). 
Fragment presence, orientation, and quality (absence of nucleotide mismatches) were 
confirmed by direct sequence analysis (Yale Keck Facility).  
Together with pGL4.18/fragment transfection, H9C2 cells were transfected with 
the pGL4.75 vector containing the CMV promoter to be used as a control. This control 
plasmid was later used to normalize signal to the number of transfected cells. Briefly, 
H9C2 cells were plated on 60-mm plates and transfected at 65-80% confluency. FuGene 
6.0 (Roche) was used as a transfection reagent. Maximum transfection efficiency was 
achieved by using 6 µl of FuGene 6.0 and 2 µg of target and 2 µg of control plasmid.   
After transfection, half of the cells were treated with 1 mM AICAR while the 
other half of the cells remained in control culture media. One hour later, all cells were 
harvested with 300 μl of 0.25% trypsin/EDTA, centrifuged to sediment the cells, 
resuspended in 100 µl of fresh media, and mixed with 100 µl of DualGlo (Promega) 
luciferase reagent/buffer mixture as described in the kit’s instructions. After twenty 
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minutes of incubation at room temperature, chemiluminescence was measured using a 
luminometer (Turner Designs). Results were recorded and 100 µl of 1:100 Stop and Glo 
(Promega) reagent/buffer mixture was added to each sample. The samples were incubated 
at room temperature for an additional twenty minutes after which luminescence was 
measured again. The firefly luciferase chemiluminescence (measured after DualGlo 
reagent addition) revealed UCP3 transcription in response to AMPK activation or in the 
absence of this stimulus (control). The CMV Renilla promoter-driven luciferase, 
measured after addition of Stop and Glo reagent, served as a control to standardize data 
between samples. Luciferase chemiluminescence for each sample was normalized to 
CMV Renilla chemiluminescence for the same sample to control for transfection 
efficiency and cell number. The normalized data from experimental samples were then 




Data are reported as mean values +/- standard deviation. Means were compared to 
control values and to each other with student’s t-tests (GB-Stat PPC SchoolPak) and two-




Activation of AMPK by AICAR 
As discussed above, phosphorylation of the threonine-172 residue of the α-
subunit of AMPK is necessary for covalent enzyme activation. As was expected, AICAR 
induced phosphorylation (and activation) of AMPK at both one and twenty-four hours of 
treatment in H9C2 cells. These data confirm that AMPK is activated under the 




Figure 6. AMPK activation as a result of 1 hour of AICAR treatment. Phosphorylation of the Thr172 
residue of the AMPKα subunit is indicative of activation. Treatment of H9C2 cells and subsequent protein 
isolation and immunoblotting demonstrated that pAMPK levels were significantly increased in AICAR 




Figure 7. AMPK activation as a result of 24 hours of AICAR treatment. After 24 hours of treatment of 
H9C2 cells with AICAR a significant difference in Thr172 phosphorylation (AMPK activation) is 
observed. pAMPK density was normalized to Actin. N=5. 
 
AICAR effect on UCP mRNA in mouse ventricle 
In the isolated tissue model utilizing mouse ventricular slices, activation of 
AMPK by AICAR induced significant increases in UCP2 and UCP3 mRNA at both the 
1-hour and 24-hour time points. Interestingly, there was a much greater increase in the 
expression of UCP3 mRNA after 24 hours of AMPK activation when compared to UCP2 
mRNA. These data suggest that AMPK activation may play a role in upregulating the 
expression of the mitochondrial uncoupling proteins in the heart. 
 
Figure 8. Mouse ventricle incubation with AICAR leads to increased UCP2 and UCP3 mRNA levels. 
Isolated 1 mm slices of mouse ventricle were incubated in a buffer solution with or without AICAR. After 
1 hour or 24 hours, samples were snap frozen in liquid nitrogen and subsequently mRNA isolated from 
them. qRTPCR was performed yielding data as summarized above. Both UCP2 and UCP3 mRNA were 
significantly increased at both time points as compared to 1 hour and 24 hour controls. 
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AICAR effect on UCP3 mRNA in H9C2 cells 
To further confirm this association, H9C2 cells were treated with AICAR for 1- or 
24-hour periods, and mRNA expression was quantified by qRTPCR. After 1 hour 
incubation with AICAR, a trend towards an increase in the expression of UCP2 on the 
mRNA level was observed. In contrast, the expression of UCP3 mRNA was statistically 
unchanged from control levels. 
 
Figure 9. UCP mRNA expression in a cellular model after 1 hour AICAR treatment. H9C2 cells were 
treated with 1 mM AICAR for 1 hour after which cells were harvested and mRNA isolated. qRTPCR 
revealed a trend towards increased UCP2 mRNA with inconclusive UCP3 results. N=4. 
 
 After H9C2 cells were incubated with AICAR for 24-hours, a small but 
statistically significant increase in UCP2 mRNA was observed, while UCP3 mRNA 
levels remained unchanged compared to control levels. 
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Figure 10. UCP mRNA expression in a cellular model after 24 hours of AICAR treatment. H9C2 cells were 
treated with 1mM AICAR for 24 hours after which cells were harvested and mRNA isolated. qRTPCR 
revealed a small but significant increase in UCP2 mRNA but no significant change in UCP3 mRNA. N=4. 
 
  
AICAR effects on UCP protein expression in H9C2 Cells 
Consistent with the mRNA results in the cellular model, immunoblots of UCP2 
protein from H9C2 cells treated with AICAR demonstrated significantly increased UCP2 
protein expression as compared to the controls samples after both one and twenty-four 
hours of incubation with AICAR. 
 
Figure 11. UCP2 protein expression in H9C2 cells after 1 hour of AICAR treatment. Western Blot 
densitometric analysis demonstrated a significant increase of UCP2 protein in AICAR treated cells as 





Figure 12. UCP2 protein expression in H9C2 cells after 24 hours of AICAR treatment. Western blot 
densitometric analysis demonstrated a small but statistically significant increase in UCP2 protein after 
AMPK activation through AICAR treatment for 24 hours. Data normalized to cytochrome c loading 
controls. N=6. 
 
Treatment of H9C2 cells with AICAR for 1 hour did not result in an increase in 
the level of UCP3 protein expression (data not pictured). In contrast, H9C2 incubation 
with AICAR for 24 hours demonstrated a dramatic increase in UCP3 protein expression, 
with the AICAR treatment resulting in UCP3 protein levels that were more than 15-fold 
higher than control samples. 
 
Figure 13. UCP3 protein expression in H9C2 cells after 24 hours of AICAR treatment. Western blot reveals 
a dramatic increase in UCP3 protein in AICAR treated cells as compared to controls. Data normalized to 




AMPK activation and the UCP3 promoter 
In the UCP3 promoter studies, a clear increase in firefly luciferase activity was 
noted when H9C2 cells with the “middle” promoter construct were treated with AICAR 
for one hour. In contrast, there was no increase in transcriptional activity in response to 
AICAR for the “left” or “right” sections of the promoter. A large increase in luciferase 
activity for the “long” construct with AICAR treatment was noted as well, though there 
was a large degree of variation between measurements for this construct, and the 
increased response of the “long” fragment, while impressive, remained statistically 
insignificant. 
 
Figure 14. Luciferase UCP3 promoter constructs response to AMPK activation with AICAR. Left panel 
summarizes data from “fragment” UCP3 promoter constructs while right panel summarizes entire promoter 
response, both compared to control. After 1 hour of incubation with 1mM AICAR, the entire promoter, 
“Long,” demonstrates trend towards increased luminescence. The “middle” fragment construct has 




These studies were performed to determine if AMPK activation results in an 
increase in the expression of UCPs in the heart. We first demonstrated that the 
pharmacologic activator, AICAR, increased AMPK phosphorylation in heart muscle both 
after one hour and 24 hours of incubation. We then demonstrated that AMPK activation 
was associated with increased expression of UCP2 and UCP3 mRNA at either 1 or 24 
hours of stimulation with AICAR in adult mouse heart slices. In contrast, in H9C2 
myocyte cultures, the changes in UCP mRNA were much less pronounced with only 
UCP2 reaching statistical significance. However, we found little correlation between the 
expression of the UCP mRNAs and expression of the UCPs on the protein level. 
Specifically, there was only a small increase in UCP2 protein with AICAR incubation 
while there was a dramatic 15-fold increase in the expression of UCP3 by 24 hours of 
AMPK stimulation by AICAR. With respect to the regulation of UCP expression by 
AMPK activation, we found that there is a region within the promoter region between -
1600 and -697 bp upstream of the start codon that contains element(s) potentially 
regulated by AMPK activation.  
 
Table 3. Summary of UCP2 and UCP3 response to AICAR. 
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Using isolated mouse ventricle slices as a tissue model, we have demonstrated 
that AMPK activation by AICAR leads to statistically significant increases in UCP2 and 
UCP3 mRNA at both one-hour and twenty-four-hour time points. Interestingly, when 
using a similar protocol in the H9C2 cellular model, UCP mRNA response was less 
striking. UCP2 mRNA appeared to trend towards an increase at one hour and a small but 
statistically significant increase was observed at twenty-four hours. No significant 
difference in UCP3 mRNA was detected after either one hour or twenty-four hour 
incubation with AICAR. This was particularly surprising given the robust response of 
UCP3 at 24 hours in the mouse model. 
These discrepant results might be explained by the fact that there is considerable 
variation in UCP expression (and by extension, regulation) between different species and 
even between different tissues within the same species. However, one would not expect 
the observed UCP3 immunoblot results: while there was no difference between UCP3 
protein levels in H9C2 mitochondrial isolations after one hour of AICAR incubation, 
there was a striking increase in UCP3 protein in the cells incubated for 24 hours with 
AICAR as compared to control samples. It is possible that there was a transient increase 
in UCP3 mRNA at some time between one and twenty-four hours which had decayed by 
the time points that were analyzed while the increase in protein expression remained 
detectable. Alternatively, another potential explanation for the discrepancy between UCP 
protein and mRNA results is suggested by the following previous studies. UCP2 protein 
has been shown to increase up to 12-fold in mouse lung and stomach following 
lipopolysaccharide treatment without any corresponding increase in UCP2 mRNA, a 
result that these authors attributed to translational regulation.98 Such translational 
 47
regulation may also contribute to determining UCP3 protein expression levels. In either 
case, it was clear that 24-hour incubation of H9C2 cells with 1mM AICAR led to a 
significant increase in UCP3 protein levels.  
Given the evidence that AMPK activation regulates increased UCP expression in 
skeletal muscle, and that this effect is likely mediated through modification of genetic 
expression through AMPK translocation to the nucleus and/or AMPK-driven activation 
of various transcription factors, we hypothesized that AMPK would employ a similar 
mechanism in the heart. Specifically, AMPK activation was hypothesized to regulate 
UCP2 and 3 expression by influencing cellular transcription. In constructing UCP3 
promoter “fragments” we hoped to identify a region of the gene where activated AMPK 
acts to induce increased expression of UCP3. Our results support the conclusion that such 
a region exists somewhere between -1600 and -697 base pairs upstream of the 
transcription start site. Further characterization of this site and the possible mechanism of 
interaction remain to be investigated. 
Limitations 
A limit to our study includes the incomplete identification of the UCP3 promoter 
site referenced above, as well as a lack of in vivo data to support our experimental 
models. Given the cross-species variation of UCP expression, it is also not unreasonable 
to question whether data from mouse and rat models can be generalized to humans. 
Although most data concerning UCP expression and function in the heart thus far support 
a system relatively conserved across these species, further investigation in humans is 
warranted. 
Similarly, although recent research has indicated that UCP3 protein is present in 
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the adult heart, while there remains a considerable degree of controversy as to whether 
UCP2 protein is expressed in cardiomyocyte mitochondria.97 Our decision to investigate 
the UCP3 promoter, and not UCP2, was influenced by this uncertainty. Nevertheless, our 
findings of UCP2 protein in H9c2 preparations support the conclusion that UCP2 may, in 
fact, be expressed in the myocardium. 
Yet our choice of cellular model may also be interpreted as a limitation. The 
H9C2 cell line was derived from fetal rat cardiomyocytes to allow for multiplication in 
culture.95 Adult cardiomyocytes are terminally differentiated and must be repeatedly 
obtained from sacrificed animals. This is labor-intensive and difficult. While 
advantageous in this respect, H9C2 cells are not ideal in that they do not completely 
retain the characteristics of isolated (or in vivo) adult cardiomyocytes. For example, 
H9C2 cells lack the gap junctions, caveolae, T tubules, and microfibriller sarcomeres of 
freshly prepared cardiomyocytes. Nevertheless, the composition of the surface coat as 
well as many of the ion channels and signaling proteins remain similar or identical 
between the immortalized H9C2 cell line and the isolated cardiomyocte.99 Further studies 
employing an isolated cardiomyocyte model, while laborious, would strengthen the 
observations made in this study. 
A further minor limitation of our study is our method of verifying AMPK 
activation. In addition to pAMPK immunoblotting, we could have checked downstream 
ACC activation or performed AMPK activity assays to prove AMPK activation. 
However, given the general agreement that phosphorylation is indicative of activation, 
we felt that such measures would be superfluous.  
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It should be noted, however, that AICAR is a relatively nonspecific activator of 
AMPK and, as such, upregulation of the UCPs upon AICAR treatment does not 
specifically prove a cause and effect relationship between AMPK activation and 
increased UCP expression, although it does strongly support such a conclusion.94 To 
remove any doubt that activated AMPK causes UCP upregulation, further experiments 
could be conducted treating an AMPK deficient model (AMPK KD cardiomyocytes or 
H9C2 cells transfected with an AMPK KD vector) with AICAR in an attempt to observe 
a lack of UCP response.  
Clinical Support 
Despite the limitations of our study, previous data support our conclusions. The 
chemical activator of AMPK, AICAR, has previously been used in clinical trials as a 
cardioprotective agent (although this was not done specifically to upregulate UCPs, or 
even to phosphorylate AMPK).  A meta-analysis of studies employing acadasine (the 
formulary name for AICAR) to treat patients before and after coronary artery bypass 
graft surgery demonstrated that treatment with the drug yielded moderate benefits. 
Specifically, acadesine decreased the need for left ventricular assist devices, the number 
of peri-operative myocardial infarctions, and the number of post-operative cardiac deaths 
when compared to placebo treatment.100 Acadasine was developed as an adenosine 
reuptake inhibitor to promote activation of adenosine receptors in the ischemic heart and 
to potentially help replenish depleted myocardial stores of GTP and ATP.69 The drug was 
ultimately abandoned because it only weakly augmented the adenosine pathway. The 
relatively modest effects could be explained by the fact that AICAR is only a weak 
activator of AMPK.70, 94 Furthermore, AICAR is not an ideal activator because it must be 
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converted to ZMP through phosphorylation to exert its effects, and has significant side 
effects including bradycardia and hypoglycemia.68  
 At the time the clinical studies using AICAR were conducted, the actions of this 
chemical were incompletely understood. Neither activation of AMPK nor upregulation of 
the UCPs was considered as a potentially cardioprotective mechanism. Nevertheless, the 
moderately successful results of this drug may be explained by this pathway, and provide 
important human, clinical evidence that AICAR activation of AMPK (and potential 
upregulation of cardiac UCPs) improves outcomes after exposure to hypoxia/ischemia. 
Future Directions 
UCPs have many important potential clinical benefits including protection of the 
heart during periods of ischemia and reperfusion, as well as a role in the prevention of 
heart failure. Our results support the idea that AMPK activation induces UCP 
upregulation through a mechanism involving interaction with the UCP promoter. 
However, some pieces of the puzzle remain missing. For example, we do not yet have 
data as to the promoter response after 24 hours of AICAR incubation, though we expect 
that the “Middle” fragment will yield increased luciferase activity as was observed in the 
1 hour incubations. Further experiments will cull the size of the promoter fragments until 
we have isolated the nucleotide sequence that appears to be responsible for the AMPK-
induced upregulation of UCP3. We also hope to identify potential transcription factors 
that might interact with this region. Finally, we will confirm the involvement of AMPK 
in the upregulation of the UCPs through the use of AMPK KO mouse models or AMPK 
deficient cell lines (as mentioned above). We believe that future studies of the role of 
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AICAR in UCP regulation utilizing in vivo animal models and human subjects will 




We hypothesized that one of the pathways responsible for increased expression of 
cardiac uncoupling proteins involves activation of AMP-activated protein kinase.  Our 
data show that pharmacologic AMPK activation with the AMP-mimetic, AICAR, leads 
to increased levels of UCP2 and UCP3 mRNA in an isolated tissue model.  We have 
further shown that UCP2 and UCP3 protein expression in a cellular cardiomyocyte model 
is increased as a result of AICAR treatment. Finally, we have identified a 1000 base pair 
region of the UCP3 promoter which appears to mediate AMPK-activated UCP 
transcriptional upregulation. Taken together, these data support the idea that activation of 





1. Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev 
1984;64:1-64. 
2. Fleury C, Neverova M, Collins S, et al. Uncoupling protein-2: a novel gene linked 
to obesity and hyperinsulinemia. Nat Genet 1997;15:269-72. 
3. Gimeno RE, Dembski M, Weng X, et al. Cloning and characterization of an 
uncoupling protein homolog: a potential molecular mediator of human thermogenesis. 
Diabetes 1997;46:900-6. 
4. Sack MN. Mitochondrial depolarization and the role of uncoupling proteins in 
ischemia tolerance. Cardiovasc Res 2006;72:210-9. 
5. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling 
proteins in human heart. Lancet 2004;364:1786-8. 
6. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. UCP3: an uncoupling 
protein homologue expressed preferentially and abundantly in skeletal muscle and brown 
adipose tissue. Biochem Biophys Res Commun 1997;235:79-82. 
7. Matsuda J, Hosoda K, Itoh H, et al. Cloning of rat uncoupling protein-3 and 
uncoupling protein-2 cDNAs: their gene expression in rats fed high-fat diet. FEBS Lett 
1997;418:200-4. 
8. Jaburek M, Varecha M, Gimeno RE, et al. Transport function and regulation of 
mitochondrial uncoupling proteins 2 and 3. J Biol Chem 1999;274:26003-7. 
9. Kontani Y, Wang Z, Furuyama T, Sato Y, Mori N, Yamashita H. Effects of aging 
and denervation on the expression of uncoupling proteins in slow- and fast-twitch 
muscles of rats. Journal of Biochemistry 2002;132:309-15. 
10. Bing C, Brown M, King P, Collins P, Tisdale M, Williams G. Increased gene 
expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 
in MAC16-induced cancer cachexia. Cancer Res 2000;60:2405-10. 
11. Taegtmeyer H, Razeghi P, Young ME. Mitochondrial proteins in hypertrophy and 
atrophy: a transcript analysis in rat heart. Clin Exp Pharmacol Physiol 2002;29:346-50. 
 54
12. Jezek P. Fatty acid interaction with mitochondrial uncoupling proteins . Review 
66 refs. Journal of Bioenergetics & Biomembranes;31:457-66. 
13. Jezek P. Possible physiological roles of mitochondrial uncoupling proteins --
UCPn. Review 100 refs. International Journal of Biochemistry & Cell Biology;34:1190-
206. 
14. Bezaire V, Hofmann W, Kramer JK, Kozak LP, Harper ME. Effects of fasting on 
muscle mitochondrial energetics and fatty acid metabolism in Ucp3(-/-) and wild-type 
mice. American Journal of Physiology - Endocrinology & Metabolism 2001;281:E975-
82. 
15. Garcia-Martinez C, Sibille B, Solanes G, et al. Overexpression of UCP3 in 
cultured human muscle lowers mitochondrial membrane potential , raises ATP/ADP 
ratio, and favors fatty acid vs. glucose oxidation. FASEB Journal 2001;15:2033-5. 
16. Hong Y, Fink BD, Dillon JS, Sivitz WI. Effects of adenoviral overexpression of 
uncoupling protein-2 and -3 on mitochondrial respiration in insulinoma cells. 
Endocrinology 2001;142:249-56. 
17. Douette P, Sluse FE. Mitochondrial uncoupling proteins : new insights from 
functional and proteomic studies. Review 108 refs. Free Radical Biology & Medicine 
2006;40:1097-107. 
18. Matthias A, Ohlson KB, Fredriksson JM, Jacobsson A, Nedergaard J, Cannon B. 
Thermogenic responses in brown fat cells are fully UCP1-dependent. UCP2 or UCP3 do 
not substitute for UCP1 in adrenergically or fatty scid-induced thermogenesis. J Biol 
Chem 2000;275:25073-81. 
19. Liu SS. Generating, partitioning, targeting and functioning of superoxide in 
mitochondria. Biosci Rep 1997;17:259-72. 
20. Vidal-Puig AJ, Grujic D, Zhang CY, et al. Energy metabolism in uncoupling 
protein 3 gene knockout mice. J Biol Chem 2000;275:16258-66. 
21. Mattiasson G, Shamloo M, Gido G, et al. Uncoupling protein-2 prevents neuronal 
death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 
2003;9:1062-8. 
 55
22. Bechmann I, Diano S, Warden CH, Bartfai T, Nitsch R, Horvath TL. Brain 
mitochondrial uncoupling protein 2 (UCP2): a protective stress signal in neuronal injury. 
Biochem Pharmacol 2002;64:363-7. 
23. Teshima Y, Akao M, Jones SP, Marban E. Uncoupling protein-2 overexpression 
inhibits mitochondrial death pathway in cardiomyocytes. Circ Res 2003;93:192-200. 
24. Bienengraeber M, Ozcan C, Terzic A. Stable transfection of UCP1 confers 
resistance to hypoxia/reoxygenation in a heart-derived cell line. J Mol Cell Cardiol 
2003;35:861-5. 
25. Hoerter J, Gonzalez-Barroso MD, Couplan E, et al. Mitochondrial uncoupling 
protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion 
damage. Circulation 2004;110:528-33. 
26. Guo P, Mizushige K, Noma T, et al. Association of uncoupling protein-2 
expression with increased reactive oxygen species in residual myocardium of the 
enlarged left ventricle after myocardial infarction. Heart Vessels 2005;20:61-5. 
27. Boss O, Samec S, Dulloo A, Seydoux J, Muzzin P, Giacobino JP. Tissue-
dependent upregulation of rat uncoupling protein-2 expression in response to fasting or 
cold. FEBS Lett 1997;412:111-4. 
28. McLeod CJ, Aziz A, Hoyt RF, Jr., McCoy JP, Jr., Sack MN. Uncoupling proteins 
2 and 3 function in concert to augment tolerance to cardiac ischemia. J Biol Chem 
2005;280:33470-6. 
29. Blanc J, Alves-Guerra MC, Esposito B, et al. Protective role of uncoupling 
protein 2 in atherosclerosis. Circulation 2003;107:388-90. 
30. Oberkofler H, Iglseder B, Klein K, et al. Associations of the UCP2 gene locus 
with asymptomatic carotid atherosclerosis in middle-aged women. Arterioscler Thromb 
Vasc Biol 2005;25:604-10. 
31. Dhamrait SS, Stephens JW, Cooper JA, et al. Cardiovascular risk in healthy men 
and markers of oxidative stress in diabetic men are associated with common variation in 
the gene for uncoupling protein 2. Eur Heart J 2004;25:468-75. 
32. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 
2005;115:500-8. 
 56
33. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, 
inflammatory cytokines, and oxidative stress. Lancet 1998;352 Suppl 1:SI34-8. 
34. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. 
Increased malondialdehyde in peripheral blood of patients with congestive heart failure. 
Am Heart J 1996;131:146-52. 
35. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-
iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential 
role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. 
Circulation 1998;97:1536-9. 
36. Baumer AT, Flesch M, Wang X, Shen Q, Feuerstein GZ, Bohm M. Antioxidative 
enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 
2000;32:121-30. 
37. Sam F, Kerstetter DL, Pimental DR, et al. Increased reactive oxygen species 
production and functional alterations in antioxidant enzymes in human failing 
myocardium. J Card Fail 2005;11:473-80. 
38. Nojiri H, Shimizu T, Funakoshi M, et al. Oxidative stress causes heart failure with 
impaired mitochondrial respiration. J Biol Chem 2006;281:33789-801. 
39. Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the 
SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated 
cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999;261:332-9. 
40. Valenti L, Conte D, Piperno A, et al. The mitochondrial superoxide dismutase 
A16V polymorphism in the cardiomyopathy associated with hereditary 
haemochromatosis. J Med Genet 2004;41:946-50. 
41. Nakamura K, Kusano KF, Matsubara H, et al. Relationship between oxidative 
stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 
2005;11:117-23. 
42. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-
induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. 
Diabetes 2003;52:777-83. 
43. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 
2007;115:3213-23. 
 57
44. Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced 
cardiac efficiency in diabetes. Physiology (Bethesda) 2006;21:250-8. 
45. Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. Importance of 
antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. 
Am J Physiol Heart Circ Physiol 2004;287:H1003-12. 
46. Gao F, Chen J, Lopez BL, et al. Comparison of bisoprolol and carvedilol 
cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 
2000;406:109-16. 
47. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione 
peroxidase prevents left ventricular remodeling and failure after myocardial infarction in 
mice. Circulation 2004;109:544-9. 
48. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of 
incident heart failure in the population. Eur Heart J 2001;22:228-36. 
49. Young ME, Patil S, Ying J, et al. Uncoupling protein 3 transcription is regulated 
by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB 
Journal 2001;15:833-45. 
50. Razeghi P, Young ME, Ying J, et al. Downregulation of metabolic gene 
expression in failing human heart before and after mechanical unloading. Cardiology 
2002;97:203-9. 
51. Neubauer S. The failing heart--an engine out of fuel. New England Journal of 
Medicine 2007;356:1140-51. 
52. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. 
Circulation 2007;116:434-48. 
53. Hesselink MK, Schrauwen P. Uncoupling proteins in the failing human heart: 
friend or foe? Lancet 2005;365:385-6. 
54. Selwyn AP, Braunwald E. Ischemic Heart Disease. In: Kasper DL, et. al., eds., ed. 
Harrisons's Internal Medicine. 16th edition ed. Online Resource: McGraw-Hill 
Companies; 2007. 
55. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 
2007;93:1137-46. 
 58
56. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer 
RJ. Burden of systolic and diastolic ventricular dysfunction in the community: 
appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. 
57. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' 
than cancer? Five-year survival following a first admission for heart failure. Eur J Heart 
Fail 2001;3:315-22. 
58. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to 
hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 
1993-2001. Heart 2003;89:615-20. 
59. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A 
Bayesian meta-analysis. Ann Intern Med 2001;134:550-60. 
60. Mark DB. Economics of treating heart failure . American Journal of Cardiology 
1997;80:33H-8H. 
61. Young ME, Patil S, Ying J, et al. Uncoupling protein 3 transcription is regulated 
by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 
2001;15:833-45. 
62. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K. Plasma free fatty acids 
and peroxisome proliferator-activated receptor alpha in the control of myocardial 
uncoupling protein levels. Diabetes 2005;54:3496-502. 
63. Zhou M, Lin BZ, Coughlin S, Vallega G, Pilch PF. UCP -3 expression in skeletal 
muscle : effects of exercise, hypoxia, and AMP-activated protein kinase. American 
Journal of Physiology - Endocrinology & Metabolism 2000;279:E622-9. 
64. Stoppani J, Hildebrandt AL, Sakamoto K, Cameron-Smith D, Goodyear LJ, 
Neufer PD. AMP-activated protein kinase activates transcription of the UCP3 and HKII 
genes in rat skeletal muscle. Am J Physiol Endocrinol Metab 2002;283:E1239-48. 
65. Jorgensen SB, Wojtaszewski JF, Viollet B, et al. Effects of alpha-AMPK 
knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J 
2005;19:1146-8. 
66. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade 
inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS 
Letters 1987;223:217-22. 
 59
67. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic 
regulation . Review 112 refs. Journal of Clinical Investigation 2006;116:1776-83. 
68. Young LH, Li J, Baron SJ, Russell RR. AMP - activated protein kinase : a key 
stress signaling pathway in the heart. Review 93 refs. Trends in Cardiovascular Medicine 
2005;15:110-8. 
69. Hardie DG. AMP-activated protein kinase: the guardian of cardiac energy status . 
comment . Review 20 refs Comments Comment on: J Clin Invest. 2004 Aug;114(4):495-
503; PMID: 15314686. Journal of Clinical Investigation 2004;114:465-8. 
70. Hardie DG. Minireview : the AMP-activated protein kinase cascade : the key 
sensor of cellular energy status . Review 66 refs. Endocrinology 2003;144:5179-83. 
71. Woods A, Cheung PC, Smith FC, et al. Characterization of AMP-activated 
protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in 
vitro. Journal of Biological Chemistry 1996;271:10282-90. 
72. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein 
kinase subfamily. Journal of Biological Chemistry 1996;271:611-4. 
73. Li J, Coven DL, Miller EJ, et al. Activation of AMPK alpha- and gamma-isoform 
complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol 
2006;291:H1927-34. 
74. Salt I, Celler J, Hawley S, et al. AMP-activated protein kinase: greater AMP 
dependence, and preferential nuclear localization, of complexes containing the alpha2 
isoform. Biochem J 1998;334:177-87. 
75. Kemp BE, Stapleton D, amp, et al. AMP - activated protein kinase , super 
metabolic regulator . Review 78 refs. Biochemical Society Transactions 2003;31:162-8. 
76. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. The 
Ca2+/calmodulin-dependent protein kinase kinase s are AMP - activated protein kinase 
kinase s. Journal of Biological Chemistry 2005;280:29060-6. 
77. Davies SP, Helps NR, Cohen PT, Hardie DG. 5'-AMP inhibits dephosphorylation 
, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies 
using bacterially expressed human protein phosphatase-2C alpha and native bovine 
protein phosphatase-2AC. FEBS Letters 1995;377:421-5. 
 60
78. Polekhina G, Gupta A, Michell BJ, et al. AMPK beta subunit targets metabolic 
stress sensing to glycogen. Current Biology 2003;13:867-71. 
79. Russell RR, 3rd, Li J, Coven DL, et al. AMP-activated protein kinase mediates 
ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and 
injury . Journal of Clinical Investigation 2004;114:495-503. 
80. Coven DL, Hu X, Cong L, et al. Physiological role of AMP-activated protein 
kinase in the heart : graded activation during exercise. American Journal of Physiology - 
Endocrinology & Metabolism 2003;285:E629-36. 
81. Russell RR, 3rd, Bergeron R, Shulman GI, Young LH. Translocation of 
myocardial GLUT-4 and increased glucose uptake through activation of AMPK by 
AICAR. American Journal of Physiology 1999;277:H643-9. 
82. Xing Y, Musi N, Fujii N, et al. Glucose metabolism and energy homeostasis in 
mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein 
kinase. Journal of Biological Chemistry 2003;278:28372-7. 
83. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart 
PFK -2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Current 
Biology 2000;10:1247-55. 
84. Jager S, Handschin C, St-Pierre J, Spiegelman B. AMP-activated protein kinase 
(AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. proc Natl 
Acad Sci U S A 2007;104:12017-22. 
85. Putman C, Kiricsi M, Pearcey J, et al. AMPK Activation Increases UCP-3 
Expression and Mitochondrial Enzyme Activities in Rat Muscle without Fibre Type 
Transitions -- Putman et al., 10.1113/jphysiol.2003.040691 -- The Journal of Physiology 
Online. J Physiol 2003;551:169-78. 
86. McGee S, Howlett K, Starkie R, Cameron-Smith, D, Kemp B, Hargreaves M. 
Exercise increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes 
2003;52:926-8. 
87. Lee M, Hwang J, Lee H, et al. AMP-activated protein kinase activity is critical for 
hypoxia-inducible factor-1 transcriptional activity and its target gene expression under 
hypoxic conditions in DU145 cells. J Biol Chem 2003;278:39653-61. 
 61
88. Bergeron R, Ren J, Cadman K, et al. Chronic activation of AMP kinase results in 
NRF-1 activation and mitochondrial biogenesis -- Bergeron et al. 281 (6): E1340 -- AJP - 
Endocrinology and Metabolism. In; 2001:E1340-E6. 
89. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and 
metformin stimulate AMP - activated protein kinase through distinct signaling pathways. 
Journal of Biological Chemistry 2002;277:25226-32. 
90. Van Der Lee KA, Willemsen PH, Van Der Vusse GJ, Van Bilsen M. Effects of 
fatty acids on uncoupling protein-2 expression in the rat heart. FASEB Journal 
2000;14:495-502. 
91. Kageyama H, Osaka T, Kageyama A, et al. Fasting increases gene expressions of 
uncoupling proteins and peroxisome proliferator-activated receptor-gamma in brown 
adipose tissue of ventromedial hypothalamus-lesioned rats. Life Sciences 2003;72:3035-
46. 
92. Teruel T, Smith SA, Peterson J, Clapham JC. Synergistic activation of UCP-3 
expression in cultured fetal rat brown adipocytes by PPAR alpha and PPAR gamma 
ligands. Biochemical & Biophysical Research Communications 2000;273:560-4. 
93. Choi SL, Kim SJ, Lee KT, et al. The regulation of AMP-activated protein kinase 
by H(2)O(2). Biochemical & Biophysical Research Communications 2001;287:92-7. 
94. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole- 4-
carboxamide ribonucleoside . A specific method for activating AMP-activated protein 
kinase in intact cells? European Journal of Biochemistry 1995;229:558-65. 
95. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. 
Experimental Cell Research;98:367-81. 
96. Sivitz WI, Fink BD, Donohoue PA. Fasting and leptin modulate adipose and 
muscle uncoupling protein : divergent effects between messenger ribonucleic acid and 
protein expression. Endocrinology 1999;140:1511-9. 
97. Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling - protein 
homologues . Review 114 refs. Nature Reviews Molecular Cell Biology;6:248-61. 
98. Pecqueur C, Alves-Guerra MC, Gelly C, et al. Uncoupling protein 2, in vivo 
distribution, induction upon oxidative stress , and evidence for translational regulation. 
Journal of Biological Chemistry 2001;276:8705-12. 
 62
99. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. 
Morphological, biochemical, and electrophysiological characterization of a clonal cell 
(H9c2) line from rat heart. Circulation Research 1991;69:1476-86. 
100. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death 
following surgery. A meta-analysis of the 5 international randomized trials. The 
Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Jama 
1997;277:325-32. 
 
 
